Rifaximin

tab: May be taken with or without food.

Hypersensitivity. Intestinal obstruction, diarrhoea with fever and/or blood in the stool, or diarrhoea caused by pathogens Campylobacter jejuni, Shigella spp., Salmonella spp.

Patient with systemic bacterial infection. Severe hepatic impairment (Child-Pugh C). Children.

Significant: Superinfection (e.g. C. difficile-associated diarrhoea).
Blood and lymphatic system disorders: Anaemia.
Cardiac disorders: Dyspnoea.
Gastrointestinal disorders: Nausea.
General disorders and administration site conditions: Fatigue, fever.
Metabolism and nutrition disorders: Peripheral oedema.
Musculoskeletal and connective tissue disorders: Muscle spasm.
Nervous system disorders: Dizziness, headache.
Psychiatric disorders: Depression.
Respiratory, thoracic and mediastinal disorders: Nasopharyngitis.
Skin and subcutaneous tissue disorders: Pruritus.
Vascular disorders: Epistaxis.

Monitor temperature, blood in stool, changes in symptoms; changes in mental status in hepatic encephalopathy and signs of hypersensitivity.

Increased systemic exposure with ciclosporin (P-glycoprotein inhibitor). Decreased and increased INR with warfarin.

Description:
Mechanism of Action: Rifaximin is a synthetic derivative of rifamycin which inhibits bacterial RNA synthesis by irreversibly binding to the β sub-unit of bacterial enzyme DNA-dependent RNA polymerase.
Pharmacokinetics:
Absorption: Nonabsorbed from the gastrointestinal tract. Bioavailability: <0.4%. Time to peak plasma concentration: Approx 1 hour.
Distribution: Plasma protein binding: 67.5% (healthy patients); 62% (patients with hepatic impairment).
Metabolism: Extensively metabolised in the liver and mainly by CYP3A4.
Excretion: Via faeces (96.6% as unchanged drug); urine (0.32% as metabolites). Elimination half-life: 5.6 hours.

Source: National Center for Biotechnology Information. PubChem Database. Xifaxan, CID=6436173, https://pubchem.ncbi.nlm.nih.gov/compound/Xifaxan (accessed on Jan. 22, 2020)

Store between 20-25°C.

Các loại kháng sinh khác

A07AA11 - rifaximin ; Belongs to the class of antibiotics. Used in the treatment of intestinal infections.

Brayfield A, Cadart C (eds). Rifaximin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 17/09/2025.

CARSL Consulting. Xifaxan 550 mg Film-coated Tablets data sheet May 2024. Medsafe. http://www.medsafe.govt.nz. Accessed 17/09/2025.

Joint Formulary Committee. Rifaximin. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 17/09/2025.

Normicron 200 mg Film-coated Tablets (Alfasigma S.p.A.). MHRA. https://products.mhra.gov.uk. Accessed 17/09/2025.

Normix (Alfasigma S.p.A.). MIMS Philippines. http://www.mims.com/philippines. Accessed 19/09/2025.

Rifaximin 550 mg Film-coated Tablets (Norgine Pharmaceuticals Limited). MHRA. https://products.mhra.gov.uk. Accessed 17/09/2025.

Rifaximin. UpToDate Lexidrug, AHFS DI (Adult and Pediatric) Online. American Society of Health-System Pharmacists, Inc. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 17/09/2025.

Rifaximin. UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 17/09/2025.

Xifaxan Tablet (Salix Pharmaceuticals, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 17/09/2025.

Xifaxanta 200 mg Film-coated Tablets (Norgine Pharmaceuticals Limited). MHRA. https://products.mhra.gov.uk. Accessed 17/09/2025.